Read more

December 07, 2021
1 min read
Save

Study finds no pattern of MIS-A after COVID-19 vaccination

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Researchers found no pattern of multisystem inflammatory syndrome in adults following COVID-19 vaccination without previous SARS-CoV-2 infection, according to a study published in Clinical Infectious Diseases.

SARS-CoV-2 infection can trigger multisystem inflammatory syndrome in adults (MIS-A) and a similar serious illness in children, MIS-C, days or weeks after a person is sick, causing symptoms in different parts of the body.

Source: Adobe Stock.
There was no overall pattern of multisystem inflammatory syndrome in adults following COVID-19 vaccination without previous SARS-CoV-2 infection. Source: Adobe Stock.
Ermias D. Belay

In the new study, Ermias D. Belay MD, a member of the CDC’s COVID-19 response team, and colleagues explained that “MIS-A was included in the list of adverse events to be monitored as part of the emergency use authorizations issued for COVID-19 vaccines.”

“The study was initiated to follow cases of people with suspected multisystem inflammatory syndrome in adults after COVID-19 vaccination became available to learn more about MIS-A, as well as to consider and determine whether COVID-19 vaccination impacted MIS-A,” a CDC spokesperson told Healio.

For the study, Belay and colleagues assessed reports of patients with MIS-A received by the CDC after COVID-19 vaccines became available between Dec. 14, 2020, and April 30, 2021.

The assessment uncovered 20 patients who met the case definition for MIS-A, including 16 (80%) who had a preceding COVID-19-like illness a median of 26 days before MIS-A onset. All 20 patients had laboratory evidence of SARS-CoV-2 infection.

Among the 20 patients, seven (35%) had received a COVID-19 vaccine a median of 10 days before MIS-A onset and three had received a second dose of a COVID-19 vaccine 4, 17, and 22 days before MIS-A onset.

“Although seven patients were reported to have received COVID-19 vaccine, all had evidence of prior SARS-CoV-2 infection,” Belay and colleagues wrote. “Given the widespread use of COVID-19 vaccines, the lack of reporting of MIS-A associated with vaccination alone, without evidence of underlying SARS-CoV-2 infection, is reassuring.”

The CDC spokesperson told Healio that, because the illness is serious and difficult to recognize, “clinicians and health department officials should be familiar with the MIS-A case definition and ensure suspected cases are reported.”